They study showed similar effects on the NSCLC patient–derived cell lines YU-1099 (harboring EGFR G719C/S768I mutation) and YU-1092 (carrying EGFR L861Q mutation). This evidence concerns the gene EGFR and non-small cell lung carcinoma.